Researchers turn to the vascular system of plants to solve a major bioengineering problem blocking the regeneration of human tissues and organs.
Category: bioengineering – Page 5
As the race between U.S. and Chinese biotech companies heats up, the competition is particularly fierce in one field: CRISPR gene editing.
China has rapidly emerged as a global leader in CRISPR research. While much of the initial focus in the industry was on the use of the technology to develop cancer treatments, Chinese biotech firms have since moved to apply it to test therapies for rare diseases, including sickle cell disease and inherited eye disorders.
In many areas, Chinese companies have been more aggressive, pushing into diseases that their U.S. counterparts have shied away from, including in Duchenne muscular dystrophy and herpes virus. That willingness has raised eyebrows among some executives and academics in the U.S., while exciting others who fear the American regulators and companies have been too conservative.
Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with a poor prognosis. Treatment options are limited, and the development of effective therapeutics is a major challenge. Here are some current and emerging therapeutic strategies for GBM:
Current Therapies 1. Surgery: Surgical resection is the primary treatment for GBM, aiming to remove as much of the tumor as possible. 2. Radiation Therapy: Radiation therapy is used to kill remaining tumor cells after surgery. 3. Temozolomide (TMZ): TMZ is a chemotherapy drug that is used to treat GBM, often in combination with radiation therapy. 4. Bevacizumab (Avastin): Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis.
Emerging Therapies 1. Immunotherapy: Immunotherapies, such as checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and cancer vaccines, aim to stimulate the immune system to attack GBM cells. 2. Targeted Therapies: Targeted therapies focus on specific molecular pathways involved in GBM, such as the PI3K/AKT/mTOR pathway. 3. Gene Therapy: Gene therapies aim to introduce genes that can help kill GBM cells or inhibit tumor growth. 4. Oncolytic Viruses: Oncolytic viruses are engineered to selectively infect and kill GBM cells. 5. CAR-T Cell Therapy: CAR-T cell therapy involves genetically modifying T cells to recognize and attack GBM cells. 6. Small Molecule Inhibitors: Small molecule inhibitors target specific proteins involved in GBM, such as EGFR, PDGFR, and BRAF.
The emerging armamentarium of cognitive warfare with Dr. James Giordano | CSI Talks #19
Posted in bioengineering, biotech/medical, chemistry, computing, ethics, health, law, military, neuroscience, policy | Leave a Comment on The emerging armamentarium of cognitive warfare with Dr. James Giordano | CSI Talks #19
Convergent engagement of neural and computational sciences and technologies are reciprocally enabling rapid developments in current and near-future military and intelligence operations. In this podcast, Prof. James Giordano of Georgetown University will provide an overview of how these scientific and technological fields can be — and are being — leveraged for non-kinetic and kinetic what has become known as cognitive warfare; and will describe key issues in this rapidly evolving operational domain.
James Giordano PhD, is the Pellegrino Center Professor in the Departments of Neurology and Biochemistry; Chief of the Neuroethics Studies Program; Co-director of the Project in Brain Sciences and Global Health Law and Policy; and Chair of the Subprogram in Military Medical Ethics at Georgetown University Medical Center, Washington DC. Professor Giordano is Senior Bioethicist of the Defense Medical Ethics Center, and Adjunct Professor of Psychiatry at the Uniformed Services University of Health Sciences; Distinguished Stockdale Fellow in Science, Technology, and Ethics at the United States Naval Academy; Senior Science Advisory Fellow of the SMA Branch, Joint Staff, Pentagon; Non-resident Fellow of the Simon Center for the Military Ethic at the US Military Academy, West Point; Distinguished Visiting Professor of Biomedical Sciences, Health Promotions, and Ethics at the Coburg University of Applied Sciences, Coburg, GER; Chair Emeritus of the Neuroethics Project of the IEEE Brain Initiative; and serves as Director of the Institute for Biodefense Research, a federally funded Washington DC think tank dedicated to addressing emerging issues at the intersection of science, technology and national defense. He previously served as Donovan Group Senior Fellow, US Special Operations Command; member of the Neuroethics, Legal, and Social Issues Advisory Panel of the Defense Advanced Research Projects Agency (DARPA); and Task Leader of the Working Group on Dual-Use of the EU-Human Brain Project. Prof. Giordano is the author of over 350 peer-reviewed publications, 9 books and 50governmental reports on science, technology, and biosecurity, and is an elected member of the European Academy of Science and Arts, a Fellow of the Royal Society of Medicine (UK), and a Fulbright Professorial Fellow. A former US Naval officer, he was winged as an aerospace physiologist, and served with the US Navy and Marine Corps.
The landmark advance builds on a 2013 study by the team, published in Science, which described the construction of the first GRO. In that study, the researchers demonstrated new solutions for safeguarding genetically engineered organisms and for producing new classes of synthetic proteins and biomaterials with “unnatural,” or human-created, chemistries.
Ochre is a major step toward creating a non-redundant genetic code in E. coli, specifically, which is ideally suited to produce synthetic proteins containing multiple, different synthetic amino acids.
43:10 Aubrey talks about costs.
In this episode of Becoming Young, Josh and Janae sit down with legendary longevity researcher Aubrey de Grey to explore the future of aging science and what it means for human lifespan. They dive deep into the latest breakthroughs in mTOR, rapamycin, senescence, and cellular rejuvenation, uncovering how cutting-edge research is redefining what’s possible for human healthspan.
Things we discussed…
The history of aging research and why scientists once believed aging was inevitable.
Aubrey de Grey’s new mouse studies and what they reveal about reversing aging.
Rapamycin, mTOR, and autophagy—how this pathway influences longevity.
The role of senolytics and clearing aging cells to extend healthspan.
What the future holds: Are we on the verge of radically extending human lifespan?
This is a must-watch for anyone interested in biohacking, anti-aging science, and longevity breakthroughs.
Subscribe for more expert interviews on longevity, biohacking, and peak performance!
Using a systems and synthetic biology approach to study the molecular determinants of conversion, Wang et al. find that proliferation history and TF levels drive cell fate in direct conversion to motor neurons.
Awesome that Colossal is doing so well — and this is from before they announced their wooly mice accomplishment!
Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and two other extinct species, has raised a $200 million Series C at a $10.2 billion valuation from TWG Global, the investment company of Guggenheim Partners co-founder Mark Walter and the billionaire Thomas Tull. The funding comes two years after the company closed its previous round at a reported valuation of $1.5 billion.
Why did investors pour so much capital at an eye-popping valuation for a company that has yet to generate any revenue and whose flagship projects, resurrecting an extinct mammoth and Tasmanian tiger, are not expected to be completed until 2028?
“The investor base has been very impressed with the speed at which we’ve created new technologies,” Ben Lamm, Colossal Biosciences’ co-founder and CEO, told TechCrunch.
DNA holds the key to understanding life itself… From genetics and the human genome to gene editing, it shapes our health, evolution, and future… Discover how CRISPR, forensic science, and genetic engineering are transforming medicine… Explore the mysteries of ancient DNA, the role of the microbiome, and the promise of gene therapy… Personalized medicine is revolutionizing healthcare, allowing treatments tailored to our genetic code… Learn how hereditary diseases are being decoded and cured through biotechnology and DNA sequencing… The future of medicine depends on genetic research, but genetic ethics raise profound questions… The genome project has paved the way for DNA fingerprinting, cloning, and synthetic biology… With genetic modification, we are reshaping evolution itself… Will genetic testing lead to designer babies or eliminate genetic disorders? As gene therapy advancements push the limits of precision medicine, are we ready for these medical breakthroughs and DNA discoveries?
Sources.
Watson, J. D., & Crick, F. H. C. (1953). Nature, 171(4356), 737–738.
Collins, F. S., & McKusick, V. A. (2001). Science, 291(5507), 1215–1220.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). Science, 337(6096), 816–821.
Pääbo, S. (2014). Annual Review of Genetics, 38, 645–679.
Lander, E. S., Linton, L. M., Birren, B., et al. (2001). Nature, 409(6822), 860–921.
#DNABreakthroughs #GeneticsRevolution #HumanGenome #GeneTherapy #FutureOfMedicine.
YOU MAY LIKE
https://www.youtube.com/watch?v=bZWKW53XA0o.
New capabilities in DNA nanostructure self-assembly eliminate need for extreme heating and controlled cooling
Posted in bioengineering, biotech/medical, computing, genetics, nanotechnology | Leave a Comment on New capabilities in DNA nanostructure self-assembly eliminate need for extreme heating and controlled cooling
University at Albany researchers at the RNA Institute are pioneering new methods for designing and assembling DNA nanostructures, enhancing their potential for real-world applications in medicine, materials science and data storage.
Their latest findings demonstrate a novel ability to assemble these structures without the need for extreme heat and controlled cooling. They also demonstrate successful assembly of unconventional “buffer” substances including nickel. These developments, published in the journal Science Advances, unlock new possibilities in DNA nanotechnology.
DNA is most commonly recognized for its role in storing genetic information. Composed of base pairs that can easily be manipulated, DNA is also an excellent material for constructing nanoscale objects. By “programming” the base pairs that make up DNA molecules, scientists can create precise structures as small as a few nanometers that can be engineered into shapes with intricate architectures.